Gilead Sciences, Inc.
Gilead Sciences, Inc. (GILD) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · GILD · as of Sep 30, 2024
Ownership Breakdown
1,794
Institutional Holders
▲ 38 vs Q2
$87.68B
Total Inst. Value
▲ $15.92B vs Q2
1.24B
Shares Outstanding
freeFloat 99.78%
1.04B
13F Shares Held
▲ 6.10M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
GILD largest shareholders · institutional ownership
Q3 2024 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
BLACKROCK, INC. biological products, (no diagnostic substances) | 121.94M | 9.78% | 9.78% | $10.22T | Nov 13, 2024 | NEW |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 115.34M | 9.25% | 9.25% | $9.67T | Nov 13, 2024 | ▲ 81.1K |
CAPITAL WORLD INVESTORS biological products, (no diagnostic substances) | 76.55M | 6.14% | 6.14% | $6.42T | Nov 13, 2024 | ▲ 299.1K |
CAPITAL RESEARCH GLOBAL INVESTORS biological products, (no diagnostic substances) | 61.80M | 4.96% | 4.96% | $5.18T | Nov 13, 2024 | ▲ 1.37M |
STATE STREET CORP biological products, (no diagnostic substances) | 60.17M | 4.83% | 4.83% | $5.04T | Nov 14, 2024 | ▲ 841.8K |
WELLINGTON MANAGEMENT GROUP LLP biological products, (no diagnostic substances) | 34.60M | 2.77% | 2.77% | $2.90T | Nov 14, 2024 | ▲ 11.67M |
FMR LLC biological products, (no diagnostic substances) | 33.16M | 2.66% | 2.66% | $2.78T | Nov 13, 2024 | ▲ 14.68M |
DODGE & COX biological products, (no diagnostic substances) | 33.05M | 2.65% | 2.65% | $2.77T | Nov 13, 2024 | ▼ 76.6K |
GEODE CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 27.54M | 2.21% | 2.21% | $2.30T | Nov 12, 2024 | ▲ 574.4K |
NORGES BANK biological products, (no diagnostic substances) | 17.70M | 1.42% | 1.42% | $1.48T | Nov 12, 2025 | ▲ 314.2K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2024 vs prior quarter
Q3 2024
26
Increased
+44.84M shares1
New Positions
first time holders23
Decreased
−13.98M shares0
Sold Out
fully exitedNet shares change (top 50)
+30.87M
+44.84M / −13.98M
Net new holders
+4
1 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
GILD insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
17
Buy transactions
14
Sell transactions
1.21
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
O'Day Daniel Patrick Chairman & CEO | Jun 1, 2026 | Sale | 10,900 | $131.10 | $1.43M | 621.7K | Form 4 ↗ |
O'Day Daniel Patrick Chairman & CEO | Jun 1, 2026 | Sale | 3,062 | $132.22 | $404.8K | 618.6K | Form 4 ↗ |
O'Day Daniel Patrick Chairman & CEO | Jun 1, 2026 | Sale | 1,038 | $132.97 | $138.0K | 617.6K | Form 4 ↗ |
Dickinson Andrew D Chief Financial Officer | May 15, 2026 | Sale | 3,000 | $132.27 | $396.8K | 173.2K | Form 4 ↗ |
Mercier Johanna Chief Comm & Corp Aff Officer | May 15, 2026 | Sale | 7,749 | $130.29 | $1.01M | 146.0K | Form 4 ↗ |
Mercier Johanna Chief Comm & Corp Aff Officer | May 15, 2026 | Sale | 11,177 | $131.19 | $1.47M | 134.9K | Form 4 ↗ |
Mercier Johanna Chief Comm & Corp Aff Officer | May 15, 2026 | Sale | 8,374 | $132.23 | $1.11M | 126.5K | Form 4 ↗ |
Mercier Johanna Chief Comm & Corp Aff Officer | May 15, 2026 | Sale | 700 | $132.75 | $92.9K | 125.8K | Form 4 ↗ |
Bluestone Jeffrey director | Apr 30, 2026 | Award | 1,146 | — | — | 10.1K | Form 4 ↗ |
Bluestone Jeffrey director | Apr 30, 2026 | Award | 4,884 | $130.84 | $639.0K | 4.9K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Gilead Sciences, Inc. (GILD) is primarily owned by institutional investors, who hold approximately 84.0% of total shares outstanding. Company insiders own approximately 0.22%, while retail and public investors account for the remaining 15.74%.
The largest institutional shareholder of Gilead Sciences, Inc. is BLACKROCK, INC., holding approximately 121.94 million shares — equal to 9.78% of outstanding shares — as of September 30, 2024.
A total of 1,794 institutional investors currently hold GILD stock, with a combined institutional value of approximately $87.68 billion as of the most recent 13F filing period.
Frequently asked questions
GILD ownershipGilead Sciences, Inc. (GILD) is primarily owned by institutional investors, who hold approximately 84.0% of shares. The largest shareholder is BLACKROCK, INC. with a 9.78% stake. Company insiders hold 0.22%. Data sourced from SEC Form 13F as of September 30, 2024.